Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study
Year: 2018
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Background: Angiogenesis is critical to colorectal cancer (CRC) growth and metastasis. Phase I/II studies have demonstrated the efficacy of nintedanib, a triple angiokinase inhibitor, in patients with metastatic CRC. This global, randomized, phase III study investigated the efficacy and safety of nintedanib in patients with refractory CRC after failure of standard therapies. Patients and methods: Eligible patients (Eastern Cooperative Oncology Group performance status 0-1, with histologically/cytologically confirmed metastatic/locally advanced CRC adenocarcinoma unamenable to surgery and/or radiotherapy) were randomized 1 : 1 to receive nintedanib (200 mg twice daily) or placebo (twice daily), until disease progression or undue toxicity. Patients were stratified by previous regorafenib, time from onset of metastatic disease to randomization, and region. Co-primary end points were overall survival (OS) and progression-free survival (PFS) by central review. Secondary end points included objective tumor response and disease control by central review. Results: From October 2014 to January 2016, 768 patients were randomized; 765 were treated (nintedanib n = 384; placebo n = 381). Median follow-up was 13.4 months (interquartile range 11.1-15.7). OS was not improved [median OS 6.4 months with nintedanib versus 6.0 months with placebo; hazard ratio (HR), 1.01; 95% confidence interval (CI), 0.86-1.19; P = 0.8659]. There was a significant but modest increase in PFS with nintedanib versus placebo (median PFS 1.5 versus 1.4 months, respectively; HR 0.58; 95% CI 0.49-0.69; P < 0.0001). There were no complete or partial responses. Adverse events (AEs) occurred in 97% of 384 nintedanib-treated patients and 93% of 381 placebo-treated patients. The most frequent grade ≥3 AEs were liver-related AEs (nintedanib 16%; placebo 8%) and fatigue (nintedanib 9%; placebo 6%). Conclusions: The study failed to meet both co-primary end points. Nintedanib did not improve OS and was associated with a significant but modest increase in PFS versus placebo. Nintedanib was well tolerated. ClinicalTrials.gov number: NCT02149108 (LUME-Colon 1).
Source: Annals of Oncology
Institutions: Universitair Ziekenhuis Leuven, KU Leuven, National Cancer Center Hospital East, USC Norris Comprehensive Cancer Center, Istituto Oncologico Veneto, University of Pisa, Hospital Universitario Virgen del Rocío, The Christie Hospital, The Christie NHS Foundation Trust, Ospedale Policlinico San Martino, Samsung Medical Center, Hospital Universitario Ramón y Cajal, Asan Medical Center, Masaryk Memorial Cancer Institute, Aichi Cancer Center, Aichi Cancer Center Hospital, University of Campania "Luigi Vanvitelli", Boehringer Ingelheim (Germany), Boehringer Ingelheim (France), Boehringer Ingelheim (Belgium), Boehringer Ingelheim (Austria), Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, Centro de Investigación Biomédica en Red de Cáncer, Vall d'Hebron Institute of Oncology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: nintedanib, metastatic colorectal cancer, refractory colorectal cancer, angiogenesis inhibitors, angiokinase inhibitors, overall survival, progression-free survival, liver-related adverse events, fatigue, regorafenib, targeted therapy, drug safety and efficacy, locally advanced colorectal cancer, objective response, disease control rate
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2884696648
